Hemoporfin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Hemoporfin is a porphyrin derivative combined with vitamin B12 for the treatment of asthenia.
- Generic Name
- Hemoporfin
- DrugBank Accession Number
- DB16183
- Background
Hemoporfin is under investigation in clinical trial NCT03125057 (A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 598.7
Monoisotopic: 598.27913496 - Chemical Formula
- C34H38N4O6
- Synonyms
- Haematoporphyrin
- Hematoporphyrin
- Hematoporphyrin ix
- Hemoporfin
- Photodyn
- External IDs
- NSC-267084
- NSC-59265
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Asthenia Combination Product in combination with: Cyanocobalamin (DB00115) ••• ••• ••••••• ••• •••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwarePadeliporfin Hemoporfin may increase the photosensitizing activities of Padeliporfin. Porfimer sodium Hemoporfin may increase the photosensitizing activities of Porfimer sodium. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Hemoporfin. Verteporfin Hemoporfin may increase the photosensitizing activities of Verteporfin. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Hematoporphyrin dihydrochloride O535A6S0T2 17696-69-4 QCLJGYHFHNRFIL-UDHHKLSBSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- HBT6M5H379
- CAS number
- 14459-29-1
- InChI Key
- UJKPHYRXOLRVJJ-AMPAVEGJSA-N
- InChI
- InChI=1S/C34H38N4O6/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27/h11-14,19-20,36-37,39-40H,7-10H2,1-6H3,(H,41,42)(H,43,44)/b23-11-,24-12-,25-11-,26-13-,27-14-,28-14-,29-12-,30-13-
- IUPAC Name
- 3-[20-(2-carboxyethyl)-10,15-bis(1-hydroxyethyl)-5,9,14,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1,3(24),4,6,8,10,12,14,16(22),17,19-undecaen-4-yl]propanoic acid
- SMILES
- CC(O)C1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C)=C5C(C)O)C(C)=C4CCC(O)=O)C(CCC(O)=O)=C3C)=C1C
References
- General References
- AIFA: Tonogen (Cyanocobalamin, Hematoporphyrin Dihydrochloride) Oral Powder for Solution [Link]
- External Links
- ChemSpider
- 16739170
- 5164
- ChEBI
- 36162
- ChEMBL
- CHEMBL403729
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Port-wine Stains (PWS) 3 1 Completed Treatment Lung Cancer 1 Not Available Not Yet Recruiting Treatment Cholangiocarcinoma 1 Not Available Recruiting Treatment Non-Resectable Cholangiocarcinoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0372 mg/mL ALOGPS logP 2.74 ALOGPS logP 4.45 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 3.75 Chemaxon pKa (Strongest Basic) 5.06 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 172.42 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 166.91 m3·mol-1 Chemaxon Polarizability 69.15 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 247.62666 predictedDeepCCS 1.0 (2019) [M+H]+ 249.49495 predictedDeepCCS 1.0 (2019) [M+Na]+ 255.23535 predictedDeepCCS 1.0 (2019)
Drug created at December 15, 2020 18:14 / Updated at May 05, 2021 20:32